| Today’s Big NewsSep 12, 2023 |
| By Fraiser Kansteiner The companies included in the warning letter sweep are: Boiron, CVS Health, DR Vitamin Solutions, Natural Ophthalmics, OcluMed, Similasan, TRP Company and Walgreens Boots Alliance. |
|
|
|
By Gabrielle Masson To build the "best pipeline in BioMarin history," the California biotech is looking to its already approved meds as a jumping off point. |
By Conor Hale The spine and orthopedics company said that President and CEO Keith Valentine, Chief Financial Officer John Bostjancic and Chief Legal Officer Patrick Keran will be replaced, effective immediately. |
By Nick Paul Taylor CEO Nick Leschly is leading a long list of 2seventy bio employees who are heading to the exit. With rival drugs putting its approved cell therapy under pressure, the bluebird bio spinout is eliminating 176 roles and advancing fewer R&D programs internally to stretch its cash runway out to 2026. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more.
|
|
By Zoey Becker As Jazz turns the page from its long-time growth driver Xyrem and leans on a trio of newer medicines for growth, its executive roster is undergoing some changes. |
By Andrea Park Though designed to be a help, the “MRI mode” feature on many of Abbott’s implanted neuromodulation systems may turn out to be something of a hindrance for some users. |
By Nick Paul Taylor Acelyrin has given its investors a nasty shock. Months after raising $540 million in a rare biotech IPO, the company has reported the failure of its lead prospect in a phase 2b/3 inflammatory disease clinical trial, causing its share price to plummet by 58% in premarket trading. |
By Fraiser Kansteiner Xspray and BMS have settled patent litigation around their potential rivals Dasynoc and Sprycel, Xspray said Tuesday. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept. 28, 2026. |
By Andrea Park Humacyte unveiled results from a late-stage clinical trial showing that its Human Acellular Vessel approach could outperform synthetic grafts in long-term patency as well as in amputation and infection rates. |
By Annalee Armstrong CureVac has hand-picked the mRNA influenza vaccine that will advance into the phase 2 portion of a clinical trial, but the famously tight-lipped biotech is keeping the data to itself for now. |
By Zoey Becker A potentially dangerous crystal formation was found in a bottle of the drug, which is used to prevent organ rejections in transplant patients. |
By Conor Hale Axim Biotech announced that it has developed a rapid, point-of-care assay that could be used for the neurodegenerative condition, by searching for abnormal formations of a key brain protein. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, September 27, 2023 | 11am ET / 8am PTIn the rapidly evolving field of drug discovery, where the COVID-19 pandemic has further accelerated changes in working patterns, the importance of efficient teamwork, open communication, and streamlined processes throughout the Design-Make-Test-Analyze (DMTA) cycle is essential. Technology holds the potential to address these challenges by improving collaboration. Register now to learn more.
|
|
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
